Source details

IOP Conference Series: Earth and Environmental Science

Scopus coverage years: from 2010 to Present

ISSN: 1755-1307   E-ISSN: 1755-1315

Subject area: (Earth and Planetary Sciences: General Earth and Planetary Sciences)

(Environmental Science: General Environmental Science)

Source type: Conference Proceeding

[View all documents >]   [Set document alert]   💾 Save to source list   Source Homepage

CiteScore 2021
0.6   ⓘ

SJR 2021
0.202   ⓘ

SNIP 2021
0.409   ⓘ

CiteScore   CiteScore rank & trend   Scopus content coverage

ⓘ   Improved CiteScore methodology   ✖

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data

papers published in 2018-2021, and divides this by the number of publications published in 2018-2021.   Learn more >

CiteScore   2021 ˅

$$0.6 = \frac{45{,}063 \text{ Citations } 2018 - 2021}{74{,}324 \text{ Documents } 2018 - 2021}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$0.8 = \frac{60{,}010 \text{ Citations to date}}{75{,}405 \text{ Documents to date}}$$

Last updated on 05 February, 2023 • Updated monthly

CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Earth and Planetary Sciences		
└ General Earth and Planetary Sciences	#153/191	20th
Environmental Science		
└ General Environmental Science	#191/228	16th

View CiteScore methodology >   CiteScore FAQ >   Add CiteScore to your site 🔗

About Scopus

What is Scopus

Content coverage

Scopus blog

Scopus API

Privacy matters

Language

日本語版を表示する

查看简体中文版本

查看繁體中文版本

Просмотр версии на русском языке

Customer Service

Help

Tutorials

Contact us

IOP Conference Series: Earth and Environmental Science

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
United Kingdom	Earth and Planetary Sciences └ Earth and Planetary Sciences (miscellaneous)	IOP Publishing Ltd.	**34**
Universities and research institutions in United Kingdom	Environmental Science └ Environmental Science (miscellaneous)		
Media Ranking in United Kingdom	Physics and Astronomy └ Physics and Astronomy (miscellaneous)		

PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Conferences and Proceedings	17551307, 17551315	2010-2021	Homepage
			How to publish in this journal
			ees@ioppublishing.org

SCOPE

The open access IOP Conference Series: Earth and Environmental Science (EES) provides a fast, versatile and cost-effective proceedings publication service.

$\bigcirc$ Join the conversation about this journal

SJR

Total Documents

Total Cites · Self-Cites

Citations per document

- Cites / Doc. (4 years)
- Cites / Doc. (3 years)
- Cites / Doc. (2 years)

External Cites per Doc · Cites per Doc

% International Collaboration

Citable documents · Non-citable documents

Cited documents · Uncited documents

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.

Metrics based on Scopus® data as of April 2022

A

Abdel Moktader Abdel Aziz El-Sayed 4 months ago

Nahla A. El Sayed and El sayed Abdel Moktader A. 2021 IOP Conf. Ser.: Earth
Environ. Sci. 906 012004

Is this scopus or not, and what is the impact factor of this magazine?

↩ reply

Melanie Ortiz 4 months ago

Dear Abdel, thank you very much for your comment. SCImago Journal and Country Rank
uses Scopus data, our impact indicator is the SJR. We suggest you consult the Journal
Citation Report for other indicators (like Impact Factor) with a Web of Science data
source. Best Regards, SCImago Team

N

NAJI 10 months ago

Hello Dear

I participated as a corresponding author in IOP conf .series: Earth and Environment Science
877(2021)012046

I want do this IOP still in Scopus ???

kind regards

↩ reply

Melanie Ortiz 10 months ago

Dear Naji, thank you very much for your comment. We suggest you consult the Scopus
database directly. Keep in mind that the SJR is a static image (the update is made one
time per year) of a database (Scopus) which is changing every day.
The Scopus' update list can also be consulted here:
https://www.elsevier.com/solutions/scopus/how-scopus-works/content

Best Regards, SCImago Team

Alharia Dinata 2 years ago

IOP Conference Series: Earth and Environmental Science - Volume 708 is not available in Scopus.

↩ reply

Melanie Ortiz 2 years ago

Dear Alharia,
thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you contact Scopus support: https://service.elsevier.com /app/answers/detail/a_id/14883/kw/scimago/supporthub/scopus/
Best Regards, SCImago Team

Vani 2 years ago

good evening, whether this journal is Q4 or Q2 ?

↩ reply

Melanie Ortiz 2 years ago

Dear Vani,
Thank you for contacting us.
As said below, we calculate the SJR data for all the publication's types, but the Quartile's data are only calculated for Journals and Book Series.
Best regards, SCImago Team

FEROSKHAN M 2 years ago

IOP Conference Series: Earth and Environmental Science - Volume 573 is not available in Scopus. But later volumes are available. May I know when will they publish in Scopus?

↩ reply

Melanie Ortiz 2 years ago

Dear Sir/Madam,
thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you contact Scopus support: https://service.elsevier.com /app/answers/detail/a_id/14883/kw/scimago/supporthub/scopus/
Best Regards, SCImago Team

Natt 3 years ago

I would like to know the quartile of this journal. Why isn't it showing on the website?

↩ reply

Melanie Ortiz   3 years ago

Dear Natt,
Thank you for contacting us. We calculate the SJR data for all the publication's types, but the Quartile's data are only calculated for Journals and Book Series.
Best regards, SCImago Team

Nurgustaana   3 years ago

Dear SCImago Team!
I want to know previous quartiles of journal (for 2018 and 2019 years). I have tried find information about a quartile, but discovered just SJR for 2018. Could you please provide information about it?
Yours sincerely, Nurgustaana

↩ reply

Melanie Ortiz   3 years ago

Dear Nurgustaana,
Thank you for contacting us. We calculate the SJR data for all the publication types, but the Quartile data are only calculated for Journal type's publications. Best regards, SCImago Team

Mora   3 years ago

hello, how to search one of journal who publised by IOP, because when i find it by the title, they are not able in scimagojr but the publisher is available in here, thank you for the respond it means a lot

↩ reply

Melanie Ortiz   3 years ago

Dear Mora,

thank you for contacting us. Could you provide us the Title of the journal? We remember that SCImago Journal & Country Rank shows all the information have been provided by Scopus. If you didn´t localize the journal in the search engine, it means that Scopus / Elsevier has not provided us the corresponding data.

Best Regards, SCImago Team

Dr. Yousif   3 years ago

Dear Sir,

I have published a paper in Earth and Environmental Science Journal (only myself, single author) I am trying to withdraw it after 28 days of publishing online, is it possible? Could you please tell me the procedure of withdrawing a paper?
Thank you,

↩ reply

Melanie Ortiz   3 years ago

Dear Yousif,
thank you for contacting us.

We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus. Unfortunately, we cannot help you with your request, we suggest you to contact the journal's editorial staff , so they could inform you more deeply. Best Regards, SCImago Team

Agustinus Kastanya 3 years ago

need information about renking of the Journal on Scopus

↩ reply

SCImago Team

Melanie Ortiz 3 years ago

Dear Agustinus, thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you to consult the Scopus database directly. Remember that the SJR is a static image of a database (Scopus) which is changing every day. Best regards, SCImago Team

Mahipal 3 years ago

Dear Admin,

How could our journal include in your IOP?

↩ reply

SCImago Team

Melanie Ortiz 3 years ago

Dear Mahipal,
thank you for contacting us.
We suggest you to contact the IOP's editorial staff , so they could inform you more deeply. If you would like to make an application to Scopus, please contact them to help you with this issue here: https://www.elsevier.com/solutions/scopus/content/content-policy-and-selection
http://suggestor.step.scopus.com/suggestTitle/step1.cfm
Best Regards, SCImago Team

Mursalin 3 years ago

Dear SCImago Team

My name is mursalin from Jambi City, Indonesia. I have published my article titled The Effect of Temperature on MDAG Purification Using Creaming Demulsification Technique at the IOP Conference Series: Earth and Environmental Science, Volume 309, conference 1 and could be accessed at: https://iopscience.iop.org/article/10.1088/1755-1315/309/1/012068. But why until now it does not appear into Google Scholar and my account.

Please help me to resolve the issue. Thank you for your kindness. I am waiting for good news from you.

Sincerelly,
Mursalin

↩ reply

Melanie Ortiz 3 years ago

Dear Mursalin,

Thank you for contacting us. Unfortunately, we can not help you with your request. Maybe other users can help you. Best Regards, SCImago Team

Танзиля Созаева 3 years ago

Доброго времени суток! Интересует информация по квартилю журнала (издания)

← reply

Melanie Ortiz 3 years ago

Dear user, thank you very much for your request. You can consult that information in SJR website. Best Regards, SCImago Team

syaiful 5 years ago

I am very interested to send my paper to this conference

best regards

syaiful

← reply

Elena Corera 5 years ago

Dear user, in the link below you will find the information corresponding to the author's instructions of this journal. Best regards, SCImago Team
https://publishingsupport.iopscience.iop.org/author-guidelines-for-conference-proceedings/

Leave a comment

Name

Email
(will not be published)

I'm not a robot
reCAPTCHA
Privacy - Terms

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Table of contents

Volume 441

2020

2nd International Conference on Fisheries and Marine Science 26 September 2019, Surabaya, Indonesia

Open all abstracts

Preface

OPEN ACCESS   011001

Preface

+ Open abstract   ▤ View article   ⬛ PDF

OPEN ACCESS   011002

Peer review statement

+ Open abstract   ▤ View article   ⬛ PDF

Papers

Earth and Environmental Science

OPEN ACCESS   012001

The grow-out of abalone (*Haliotis squamata*) at different shelter shape on growth and survival and its marine environmental influences at Lembongan Bay coastal waters

I Ardi, E Setiadi, Rasidi and W S Pranowo

+ Open abstract   ▤ View article   ⬛ PDF

OPEN ACCESS   012002

Stocking density of Rotifera, *Hexarthra mira* on water quality and production

I Ardi, S Cahyaningsih and E Setiadi

+ Open abstract   ▤ View article   ⬛ PDF

OPEN ACCESS   012003

The effect addition of kappa carrageenan flour to the level of gel strength and acceptability of dumpling from threadfin bream fish (*Nemipterus nematophorus*) surimi

D M Astutik, L Sulmartiwi, E Saputra and D Y Pujiastuti

+ Open abstract   ▤ View article   ⬛ PDF

012004

Maximizing production of a male offspring in *Moina macrocopa* culture through manipulation of rice bran suspension concentration

A S Mubarak, D Jusadi, M Zairin Jr and M A Suprayudi

✚ Open abstract　　📄 View article　　📄 PDF

012005

The Concept of the Right to Management of Coastal Communities in the Regional Autonomy Era: Experience from Community Assistance to Obtain the Right to Manage Sea Cucumbers in Sunsak Bay, East Lombok.

A Wahyono and M Illiyani

✚ Open abstract　　📄 View article　　📄 PDF

012006

Selective breeding technique: Pandu and Kunti tilapia (*Oreochromis niloticus*) broodstock candidates at PBIAT Janti, Klaten-Central Java

S H Samara, A W Fathurrozi and Sutarno

✚ Open abstract　　📄 View article　　📄 PDF

012007

Potential of *Caulerpa racemosa* extracts as sunscreen creams

E B Ersalina, A A Abdillah and L Sulmartiwi

✚ Open abstract　　📄 View article　　📄 PDF

012008

Histopathology of the gill of Vaname Shrimp (*Litopenaeus vannamei*) infested by protozoan ectoparasite

S R Pribadi, P D W Sari and S Subekti

✚ Open abstract　　📄 View article　　📄 PDF

012009

The effect of iron powder as oxygen absorber active packaging on fish oil total oxidation value

E N Hidayah, RR J Triastuti and A A Abdillah

✚ Open abstract　　📄 View article　　📄 PDF

012010

The occurance of endoparasite helminth on Threadfin Bream (*Nemipterus japonicus*) from the fish auction place Mayangan, Probolinggo, East Java

D S Octatriana, P D W Sari and G Mahasri

✚ Open abstract　　📄 View article　　📄 PDF

012011

Comparative study of marine fish freshness based on the handling method in Puncak Permai

modern market and Simo Gunung traditional market, Surabaya

M Sari, J Triastuti, H Pramono and Sudarno

Renal Artery Stenosis: The Challenging in Diagnosis and Therapy

I P Dewi and N Mardiana

✚ Open abstract   📄 View article   📄 PDF

    012181

Plasma Histamine Level as a Distinguishing Factor between Stable Coronary Artery Disease and Acute Coronary Syndrome

I S Prihatiningsih, J N E Putranto, D Soemantri and A S Hadi

✚ Open abstract   📄 View article   📄 PDF

    012182

Correlation between Left Ventricular Function with Functional Capacity in Post Infarct Myocard Patients with Heart Failure

I Sudirman, B S Pikir and L G P Rinjani

✚ Open abstract   📄 View article   📄 PDF

    012183

Fibrinogen and Low-Density Lipoprotein (LDL) Cholesterol Levels with the Occurrence of Acute Myocardial Infarction: Is it Correlated?

I S Warno, J N E Putranto and B Novitalia

✚ Open abstract   📄 View article   📄 PDF

    012184

Supine Percutaneous Nephrolitholapaxy Profile in Jombang General Hospital from 2017 until 2018

J H Purba, F Surahmad and J Renaldo

✚ Open abstract   📄 View article   📄 PDF

    012185

The Correlation between p53 Serum Levels and Vascular Age was Measured by Carotid Intima Media Thickness (CIMT) in Patients with Moderate Cardiovascular Risk Factors

J R S Tengor, D Soemantri, J N E Putranto and B F K Putra

✚ Open abstract   📄 View article   📄 PDF

    012186

Cluster of differentiation 36 (CD 36), ENac, and AQP 2 effects on heart

J Sunariani

✚ Open abstract   📄 View article   📄 PDF

    012187

Systolic Function is Related to the Quality of Life in Chronic Heart Failure Patients

K A Shonafi, R B Wicaksono, R I Gunadi, R Herdyanto and A Andrianto

✚ Open abstract   📄 View article   📄 PDF

    012188

Correlation between Serum Galectin-3 Level with Wall Motion Score Index in Patients with ST-Segment Elevation Myocardial Infarction

K Halid, M Aminuddin and I P Dewi

+ Open abstract   📄 View article   📄 PDF

012189

The Correlation between Serum Tryptase Level and Ventricular Remodeling in Patient with Acute Coronary Syndrome After 1 Month of Onset

L D Yuni, D Soemantri and M I Ilman

+ Open abstract   📄 View article   📄 PDF

012190

Levofloxacin and Drug-Induced Long QT Syndrome (diLQTS): The Incidence and How to Prevent It

L G Catelya, C T Tjahjono and A Hanafi

+ Open abstract   📄 View article   📄 PDF

012191

The Effect of Atorvastatin Administration before Percutaneous Coronary Intervention on Stable Coronary Artery Disease Against Event of Periprocedural Myocardial Infarction

L P C Dewi, R M Yogiarto, I G R Suryawan and M D Pratama

+ Open abstract   📄 View article   📄 PDF

012192

Correlation between Arterial Stiffness with Left Ventricular Mass Index and Diastolic Function in Patients with Stage 3 and 4 of Non-Diabetic Chronic Kidney Disease

L Pramushinta, B S Pikir, Pranawa and D E Wardhani

+ Open abstract   📄 View article   📄 PDF

012193

Thrombolytic Therapy in Octogenarian Patient with STEMI at Buleleng General Hospital

M A Pasha and I K Susila

+ Open abstract   📄 View article   📄 PDF

012194

The Correlation Between Strain and Strain Rate Left Ventricle with Functional Capacity in Post Myocardial Infarction Patients with Heart Failure

M Muqsith, B S Pikir and M Rifqi

+ Open abstract   📄 View article   📄 PDF

012195

Predicting the Likelihood for Severe CAD and CABG Indication on Elective Patients: Comparison of Novel CHA2DS2-VASc-HSF with CHA2DS2 and CHA2DS2-VASc Score

M J Al-Farabi, I G P G Semita, K A Shonafi, R Ramadhiani, B Jovie and A Andrianto

+ Open abstract   📄 View article   📄 PDF

Plasma Histamine Level as a Distinguishing Factor between Stable Coronary Artery Disease and Acute Coronary Syndrome

Plasma Histamine Level as a Distinguishing Factor between Stable Coronary Artery Disease and Acute Coronary Syndrome

I S Prihatiningsih[1], J N E Putranto[1,2*], D Soemantri[1,2] and A S Hadi[1]

[1] Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia
[2] Department Cardiology and Vascular Medicine DR. Soetomo General Hospital Surabaya

* Corresponding author: nugicardio1@yahoo.com

Abstract. Background: Angina can be caused by atherosclerosis in Coronary Artery Disease (CAD) patients either in Stable Coronary Artery Disease (SCAD) or Acute Coronary Syndrome (ACS). Histamine as a mast cell-preformed mediator is suspected to play a role in atherosclerosis. However, its mechanism is yet to be established and there is a lack of these data in the CAD population. To confirm the distinctness of plasma histamine level in patients with Acute Coronary Syndrome and Stable Coronary Artery Disease Patients, this research was an observational analytic study with transversal design in 49 CAD patients by purposive sampling which consists of 25 ACS patients (72% men, mean age 55,6±9,66 years) and 24 SCAD patients (83,3% men, mean age 52,71±8,03 years). The level of plasma histamine was measured using a Histamine ELISA-Kit. Median values of plasma histamine level in ACS group and SCAD group were 30,79 ng/ml (5,85-36,09 ng/ml) and 26,42 ng/ml (0,30-41,39 ng/ml). Comparison analysis on the median value of plasma histamine level between two groups was done with Mann-Whitney U Test and showed a statistical difference between two groups (p=0,011). There are significant differences in plasma histamine level between Acute Coronary Syndrome and Stable Coronary Artery Disease Patients.

1. Introduction

Coronary Artery Disease (CAD) is the leading cause of death in many countries. Although the mortality rate from CAD has declined over the past four decades, CAD remains responsible for 1 in 6 deaths in the United States in 2009 and around one-third or more of all deaths over the age of 35 years. [1, 2, 3] Riskesdas 2013 data shows that the prevalence of CAD in the population over the age of 15 in Indonesia was 1.5% [4].

CAD are divided into acute and chronic manifestations. Acute manifestations include an Acute Coronary Syndrome (ACS) consist of Non-Elevation Acute Coronary Syndrome (NSTEACS) and ST-Elevation Myocardial Infarction (STEMI) while chronic manifestations are Stable Coronary Artery Disease (SCAD). Patients often present with chest pain or angina pectoris, which is a clinical manifestation of CAD that is often encountered in daily clinical practice. CAD patients are generally given medical therapy for anti-angina to treat their complaints. In some patients with CAD who have received anti-angina medication, some still complain of angina pectoris symptoms. The mechanism of the occurrence of angina pectoris can be caused by various things which disrupt the balance of

myocardial oxygen demand and supply, which can occur during activity or at rest and can be acute or chronic.

The process of developing a CAD is preceded by atherosclerosis in the coronary arteries. Atherosclerotic lesions can form stenotic and non-stenotic lesions [7]. Stenosis that occurs in the coronary arteries is just the "tip of the iceberg" of a widespread and diffuse process of atherosclerosis. [8] Atherosclerosis begins with the formation of fatty streaks, an accumulation of foam cells and T cells in the tunica intima. The core of atheroma is surrounded by a layer of smooth muscle cells and collagen-rich matrix. At the peripheral of atheroma, there is a massive infiltration of T cells, macrophages, and mast cells. [9][10]

These mast cells are known to play a role in modulation of atherogenesis. A high level of mast cells in the *shoulder region* of the atheroma has an enhanced effect risk of plaque rupture [9, 10, 11]. One of the mediators released by mast cells which have a role in the pathophysiology of SCAD and ACS, is histamine.

Histamine-related studies and their role in atherosclerosis have been widely carried out in vitro and in vivo in experimental animals, but histamine studies in CAD patients have not been widely performed. Based on an in vitro study, Lindstedt et al. reported that histamine causes dilatation of blood vessels so that it increases the permeability of blood vessels, resulting in local edema and withdrawal of inflammatory cells which then increases the risk of plaque erosion and rupture. The information about histamine in patients with CAD general and especially in patients with ACS and SCAD is still not widely available. Hence, this study will examine the differences in plasma histamine levels in both groups of the patients.

2. Methods

This analytic observational study used a transversal study approach. The purpose of this study is to distinguish between plasma histamine level in patients with Acute Coronary Syndrome and Stable Coronary Artery Disease Patients, and analyze the correlation between plasma histamine levels and angina degrees based on the classification of the Canadian Cardiovascular Society (CCS).

This study was conducted at the Emergency Room and Outpatient Clinic of Dr. Soetomo General Hospital Surabaya; ER's Clinical Pathology Laboratory and Diagnostic Center Building of Dr. Soetomo General Hospital Surabaya; and Laboratory of Hospital for Tropical Disease Universitas Airlangga Surabaya. The study was held at July 2015 to October 2015. The sample of this study was patients with coronary heart disease (CAD) in Surabaya during the study period. The study sample was CAD patients divided into Acute Coronary Syndrome (ACS) and Stable Coronary Artery Disease (SCAD) patients.

These are inclusion and exclusion criteria for this research.

Inclusion criteria:

- Age ≥ 20 years
- Willing to participate in research and sign an informed consent sheet
- SCAD patients, who are diagnosed based on history, physical examination, electrocardiogram (ECG) and echocardiography data, exercise stress test (EST) or previous coronary angiography
- ACS patients diagnosis based on history, physical examination, acute ECG changes and laboratory tests for cardiac marker levels (CKMB and troponin I)

Exclusion criteria:

- Have autoimmune disease
- Suffering from malignancy
- Taking anti-histamine drugs in 3 days before blood sampling
- History of taking long term corticosteroid drugs (more than 2 weeks) or short term corticosteroid (1 week) before blood sampling

Drop out criteria:

- Lysis blood samples and lipemic blood samples

The research sample was taken by purposive sampling, i.e. samples were taken from accessible populations with specific considerations until the minimum number of samples was met.

2.1. Research tools and material

Tools: syringes, vacuum blood tubes (Vacuette TM), Eppendorf tube, rack tube, the cooler device for the storage of blood samples, cooling bag, centrifugation machine, plasma histamine counter machine by the method of Enzyme Linked Immunosorbent Assays (ELISA), ECG machine, sphygmomanometer, stethoscope, stature meter and weight scales . Ingredients: 3 cc venous blood sample and Histamine ELISA Kit ABIN2115229

2.2. Research steps

ACS patients who came to the emergency room of Dr. Soetomo General Hospital and SCAD patients who came to the outpatient department were subject to an early screening according to the inclusion and exclusion criteria.

After being explained the procedure and signing an informed consent, patients with ACS and SCAD that met the inclusion and exclusion criteria were performed an anamnesis, physical examination, and the comprehensive examinations such as ECG and X-ray was checked from the past medical records. After that, 3 cc of venous blood was drawn. For patients in the SCAD group, blood sampling was carried out to the Clinical Pathology Laboratory at the Integrated Diagnostic Center Building (GPDT) Dr. Soetomo Hospital Surabaya. In patients with ACS group, blood sampling was performed during 24 hours since arriving at the Dr. Soetomo General Hospital, during the blood sampling process the patient is always accompanied by a doctor to improve patient safety.

Blood collected in vacuum blood tubes are labelled with the serial number of the sample. The blood was centrifuged immediately after collection and then plasma is taken and put in an Eppendorf tube, placed in a tube rack and then stored inside a cooler with a temperature of -2.0°C. Then the sample was taken by using a cool bag with dry ice to Laboratory of Hospital for Tropical Disease Universitas Airlangga for the examination of histamine levels in plasma by using histamine ELISA - Kit ABIN2115229 according to the protocol in the kit. After the data is collected, data analysis is performed.

2.3. Data processing and analysis

The data collection goes through a process of coding, entering, cleaning, and editing. A descriptive statistical analysis was done on the basic characteristics of the research subjects including age, sex, angina degree based on the Canadian Cardiovascular Society, ECG interpretation, Body Mass Index (BMI), SCAD history, ACS history, history of diabetes mellitus, history of hypertension, history of dyslipidemia, smoking history, history of allergies, history of previous PCI procedures, Glomerular Filtration Rate (GFR) and lipid profile as well as plasma histamine levels. To find out whether the data obtained is normally distributed, a normality test is carried out. Inferential statistical analysis was conducted to test the hypothesis of differences in plasma histamine levels between groups of ACS patients and patients with SCAD by using Independent Student t-test (if the data is normally distributed). Mann Whitney-U test used if the data is not normally distributed. The relationship between plasma histamine levels with the degree of angina based on the classification of the Canadian Cardiovascular Society was analyzed using the Spearman Rank Correlation Test. Different analysis between variables in the ACS and SCAD groups with categorical data types were performed by Chi-square (X^2) test or with Fisher's Exact Test if the cell values were small. Categorical scale data l was displayed in the form of frequency distributions and percentages, while numerical scale data will be displayed in the form of a mean ± standard intersection or median and range of values. A $p < 0.05$ indicates statistical significance [14].

Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) for Windows version 20.0.

3. Results

25 patients with ACS and 24 patients with SCAD who met the inclusion and exclusion criteria were included in this study. This number satisfies the minimum sample required as determined by the *sample size formula* that is equal to 20 research subjects for each group.

3.1. Basic characteristics of research subjects.

ACS patients consisted of 18 male subjects (72%) and 7 female subjects (28%) while the SCAD patients group consisted of 20 male subjects (83.3%) and 4 female subjects (16, 7%). The average age of the subjects in the ACS group was 55.6 ± 9.66 years, while the SCAD group was 52.71 ± 8.03 years. In the ACS group there were 1 person who had a history of SCAD (4%), 1 person with previous ACS history of (4%), 13 persons with diabetes mellitus (52%), 17 persons with hypertension (68%), 15 persons with smoking history (60%), 5 persons with history of dyslipidemia (20%), 1 person with history of Chronic Kidney Disease (CKD) (4%), and no one has a history of allergies or history of undergoing Percutaneous Coronary Intervention (PCI) before.

In the group of SCAD there were 24 persons with history of SCAD (100%), 13 persons with history of ACS (54 , 2 %), 11 persons with diabetes mellitus (45.8 %), 17 persons with hypertension (70, 8%), 18 persons with smoking history (75 %), 17 persons with history of dyslipidemia (70.8 %), 2 persons with history of CKD (8.3 %), 3 persons with history of allergy (12.5%) and 13 persons with history of having undergone previous PCI procedures (54.2%). Some other examination parameters included angina degree, Body Mass Index (BMI), Glomerular Filtration Rate (GFR) based on Cockroft-Gault, blood fat profile levels (total cholesterol, LDL, HDL, triglyceride, and ratio of total cholesterol to HDL) and an electrocardiogram. A summary of the basic characteristics of the research subjects from the two groups can be seen in table 3.1.

Table 1. Basic characteristics of the study subjects (n = 49).

Variable	*ACS* group (n = 25)	*SCAD* group (n = 24)	*P*
Gender			
Male (%)	18 (72%)	20 (83.3%)	0, 496 [d]
Female (%)	7 (28%)	4 (16.7%)	0.496 [d]
Age (years)	55.6 ± 9.66	52.71 ± 8.03	0,400 [c]
BMI (kg/m^2)	25.2 ± 2.78	25.07 ± 4.93	0.271 [c]
SCAD history (%)	1 (4%)	13 (54.2%)	<0.001 [c]
Degree of angina			
CCS I	0 (0%)	5 (20.8%)	<0.001 [c]
CCS II	0 (0%)	17 (70.8%)	<0.001 [c]
CCS III	9 (36%)	2 (8.3%)	<0.001 [c]
CCS IV	16 (64%)	0 (0%)	<0.001 [c]
ACS history (%)	1 (4%)	13 (54.2%)	<0.001 [d]
Diabetes mellitus (%)	13 (52%)	11 (45.8%)	0.666 [c]
Hypertension (%)	17 (68%)	17 (70.8%)	1,000 [d]
Dyslipidemia (%)	5 (20%)	17 (70.8%)	<0.001 [c]
Smoking history (%)	15 (60%)	18 (75%)	0.364 [d]
CKD history (%)	1 (4%)	2 (8.3%)	0.609 [d]
Allergy history (%)	0 (0%)	3 (12.5%)	0,110 [d]
Previous *PCI* history (%)	0 (0%)	13 (54.2%)	<0.001 [d]
GFR (ml / minute)	69.37 ± 27.26	77.44 ± 32.88	0.354 [a]
Total cholesterol (mg/dl)	176.76 ± 26.75	184.54 ± 39.6	0,427 [a]
LDL (mg / dl)	119.64 ± 24.21	123.13 ± 51.27	0.749 [b]
HDL (mg / dl)	29.12 ± 6.9	33.17 ± 9.39	0.042 [b]

Triglycerides (mg/dl)	167.56 ± 69.56	171.5 ± 88.77	0.889 [b]
TC/HDL ratio	6.38 ± 1.8	6.07 ± 2.67	0.267 [b]
ECG picture			
Elevation ST segment (%)	20 (80%)	0 (0%)	<0.001 [c]
ST depression or T inversion (%)	4 (16%)	4 (13.3 %)	<0.001 [c]
Pathological Q (%)	0 (0%)	14 (46.7 %)	<0.001 [c]
Normal (%)	0 (0%)	5 (16.7 %)	<0.001 [c]
Others (%)	1 (4%)	1 (3.3 %)	<0.001 [c]

Information:
Numerical scale data will be displayed in the mean ± standard intersection and analyzed by the *Independent S tent Test* (*=a) if the distribution is normal, or by *Mann-Whitney U Test* (†=b) if the distribution is not normal. Data categorical scale is displayed in the form of a frequency distribution and percentage (%) and [c] analyzed with $X^2 test$ (‡=c) or if the value of small cells with *Fisher's Exact Test* (§=d) .

3.2. Plasma histamine levels in group ACS
Plasma histamine levels in the ACS group are shown in table 2. In the ACS group, the median value of plasma histamine levels was 30.79 ng/ml with a value range of 5.86 - 36.09 ng/ml.

Table 2. Plasma histamine levels in *ACS* group (n = 25).

Variable	Median	Minimum	Maximum
Plasma Histamine Levels (ng/ml)	30.79	5.86	36.09

3.3. Plasma histamine levels in the SCAD group
Plasma histamine level data in SCAD groups are shown in table 3. In SCAD group, the median value of plasma histamine levels was 26.42 ng/ml with a range of values ranging from 0, 30 - 41.39 ng/ml.

Table 3. Plasma histamine levels in *SCAD* group (n=24).

Variable	Median	Minimum	Maximum
Plasma Histamine Levels (ng/ml)	26,42	0,30	41,39

3.4. Differences in plasma histamine levels between two groups
Analysis of differential in plasma histamine levels between ACS and SCAD patients are shown in table 4. The normality test was conducted using the Kolmogorov-Smirnov test and the resulting distribution of histamine data is not normal ($p < 0.05$), so that inferential analysis is performed using the Mann-Whitney U Test and histamine levels shown in the median between the range of minimum and maximum value. The results of the Mann-Whitney U Test showed significant differences from plasma histamine levels between ACS and SCAD patients with median values of plasma histamine levels in ACS and SCAD patients was 30.79 ng/mL and 26.42 ng/ml, respectively, wherein both the median difference was statistically significant, $p = 0.011$ ($p < 0.05$).

Table 4. Analysis of differences in plasma histamine levels between the two groups.

Variable	*ACS* Group (n=25)		*SCAD* Group (n=24)		$p^{\dagger}$
	Median	Min-Max	Median	Min-Max	
Plasma Histamine Levels (ng/ml)	30,79	5,86-36,09	26,42	0,30-41,39	0,011[a]

a: Analyzed with Mann-Whitney U Test

3.5. Plasma histamine levels based on the angina classification

Data of plasma histamine levels based on the classification of angina according to the Canadian Cardiovascular Society on the whole subject of the study are shown in table 5.

Table 5. Plasma histamine levels based on classification of angina degrees.

Degree of angina (n=49)	Plasma Histamine Level (ng/ml)		
	Median	Minimum	Maximum
CCS I	26,27	3,2	31,18
CCS II	26,44	0,3	41,39
CCS III	30,62	12,83	34,19
CCS IV	32,08	5,86	36,09

3.6. Interrelationship between plasma histamine level and degree of angina
Correlation analysis between plasma histamine levels and angina levels based on the Canadian Cardiovascular Society is shown in table 6. This inferential analysis is done using the Spearman Rank Correlation Test and the correlation was moderately positive [15] and statistically significant r (49) = +0,379, p = 0.007, two-tailed between plasma histamine levels with angina degrees. In this case, when plasma histamine levels were increased, the degree of angina was also increased.

Table 6. Correlation analysis between plasma histamine levels and angina degrees.

Variable	*P*	*r*
Plasma Histamine Levels and Degrees of Angina	0,007[a]	0,379

a Analyzed using the Spearman Rank Correlation Test

4. Discussion
This study shows the characteristics of most patients with CAD, in both groups, ACS and SCAD were male with a mean age of 55.6 ± 9.66 and 52.71 ± 8.03 years, respectively. Traditional risk factors such as diabetes mellitus, hypertension, obesity, and smoking were found in both groups but there were significant differences in the history of dyslipidemia in which the SCAD group had more subjects who have a history of dyslipidemia in 17 (70.8%). The examination of lipid profiles was performed by examining the total cholesterol, LDL, HDL, and triglycerides; there were no significant differences in characteristics of lipid profiles between two groups. These findings were in line with existing epidemiological data [16]. Clinical manifestations of coronary artery atherosclerosis in the form of angina was measured by the degree classification of The Canadian Cardiovascular Society (CCS) in which the group SCAD patients is included in the category of CCS II (70.8%), while the group of ACS is CCS IV (64%). In CAD group, no subjects experienced angina with the CCS IV classification. More than half of the patients (54.2%) in CAD group had a history of previous SCAD or ACS and had undergone PCI procedures. In ACS group, no subjects experienced angina with the CCS I and CCS II classification.

The proportion of patients from group ACS with ST-elevation as ECG result is 20 persons (80%). While non ST elevation is 5 persons (16 %) respectively. This is different from the proportion to Global Registry of Acute Coronary Events (GRACE) Study conducted in 14 countries where most of the presentations of ACS patients are NSTE-ACS which is as much as 62 % of 44,372 patients [17]. In *The Second Euro Heart Study on ACS* (EHS-ACS) conducted in 32 countries, the proportion of patients with STEMI and NSTE-ACS is almost the same amount, as much as 47% and 48% from 6385 patients [18]. This difference can be explained by the place where the research was carried out only in one hospital

which is a tertiary referral hospital and NSTE-ACS cases can already be handled by other hospitals so that not all ACS cases are referred to the research site.

In this study, the median plasma histamine level in the ACS group was 30.79 ng/ml. In a previous study by Clejan et al. in the United States, the mean histamine blood levels in ACS patients were 84.5 ± 10.9 ng/ml which was much higher than the median values obtained in the ACS group in this study. 1 5 N The median value of the ACS plasma histamine group in this study was lower than the mean value of the control patients in the Clejan et al. and Zdravkovic et al studies (30.79 ng/ml vs. 38.8 ± 8.7 ng / ml vs. 44.87 ± 1.09 ng/ml, respectively) [12,19]. Race population in this study is different from the previous study population where the difference in population can lead to differences in baseline plasma histamine levels, whereas there are no data or previous studies on plasma histamine levels in Indonesia. The study of Zdradkovic et al. reported histamine levels in the ACS group, which reached a peak in the examination 48 hours after the onset of chest pain so that in this study lower plasma histamine levels were also likely due to plasma histamine levels not yet reached its peak.[19] The range of plasma histamine levels in the ACS group was quite wide, i.e. between 5.86 - 36.09 ng / ml with blood sampling from all patients in this group was carried out in less than 24 hours after the patient arrived at IRD. These conditions can be caused by the onset of different chest pain.

In the SCAD group, the median plasma histamine level was 26.42 ng/ml. In a previous study by Clejan et al. and Zdradkovic et al., higher histamine levels were obtained, namely 73.6 ± 11.1 ng/ml and 79.5 ± 3.6 ng/ml respectively [12,19]. In both previous research reports, there was no mention of PCI in the SCAD group while in this study more than half of the respondents had undergone PCI so apart from being a population difference, a history of having undergone PCI procedures was also a factor which plays a role, but this still needs to be further proven[12,19]. Range values of plasma histamine in the SCAD group of this study were extensive, i.e. between 0.30 - 41.39 ng/ml. The cause of this wide range of values is unknown because there is no basic data to compare with the same population.

In this study, the distribution of plasma histamine level data was abnormal. Hence, the median values between both groups need to be compared with each other. In both groups, there were no differences in age, sex, BMI, risk factors for diabetes mellitus, hypertension, smoking history and lipid profile. The results showed a statistically significant difference in plasma histamine levels between the ACS group and the SCAD group, 30,79 ng/ml (value range 5.86-36.09 ng/ml) and 26.42 ng/ml (value ranges from 0.30 to 41.39 ng/ml), p = 0.011. These results are consistent with the results obtained from previous studies by Clejan et al. where there were significant differences of histamine levels in the ACS, SCAD and control groups [12]. Zdradkovic et al. also obtained similar results in which the histamine levels in the group of ACS-STEMI was significantly higher compared with SCAD and when compared with the control group value is greater about two to three times [19]. The results of this study reinforce the results of previous studies, that there are differences in levels of histamine in the spectrum of patients CAD. The lower value of overall histamine levels compared to previous studies can be caused by different populations study so that the possibility of basic histamine levels in each population is different.

Subanalysis was conducted to determine the correlation of plasma histamine levels with angina degrees based on the classification of the Canadian Cardiovascular Society [6,20]. Highest median values were obtained in the subjects with the degree of angina CCS IV, while the lowest median value was obtained on the subjects with the degree of angina CCS I. There were no other studies that correlate plasma histamine levels with angina degrees. However, from the statistical test results using the Spearman Rank Correlation Test between plasma histamine levels and angina degrees, a moderately positive correlation was found, which was statistically significant. This result shows that when plasma histamine levels increase, the degree of angina also increases. In the study of Wang et al. in mice that were genetically designed to be histamine deficiencies and compared to controls, there was less atherosclerosis in mice with histamine deficiency [21]. The results of this study reinforce the results of previous studies, where histamine can cause vasodilation and increased the permeability of capillary arteries in atherosclerotic plaques so that bleeding occurs in the plaque and consequently when the intima thickens and the lumen of the coronary arteries becomes narrower, it can also cause coronary artery spasm [13,14]. Narrowing due to atherosclerotic plaques and coronary artery spasm can also cause

angina. The histamine release in the atherosclerotic plaque will cause progression of atherosclerotic plaque, accelerate the occurrence of plaque rupture and thrombosis, which can result in occlusion of the coronary arteries [12]. As a result of the plaque rupture, histamine can be released into the circulatory system [22].

This study has weaknesses, such as the absence of a control group, and there was no preliminary study that should conducted to determine the basic value of histamine. Examination of blood samples in a laboratory with a different place from the place of blood sampling also has a potential effect in the results of histamine levels data. Because, despite various efforts to maintain the temperature both by using cool boxes and dry ice, there is still the possibility of sample damage caused by the process of thawing during the trip.

5. Conclusion

The differential in plasma histamine levels between patients with Acute Coronary Syndrome and Stable Coronary Artery Disease was statistically significant. There was also a moderate positive correlation between plasma histamine levels and angina degrees that were statistically significant.

References

[1]   Go A S, *et al*. 2013 Heart disease and stroke statistics—2013 update: a report from the american heart association *Circulation* **127** e6-e245

[2]   Naghavi M, *et al.* 2015 Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013 *Lancet* **385** 117-71

[3]   Nichols M, Townsend N, Scarborough P and Rayner M 2014 Cardiovascular disease in europe 2014: epidemiological update *Eur Heart J* **35** 2950-9

[4]   Balitbang Kemenkes RI 2013 *Riset Kesehatan Dasa*r (Jakarta: Balitbang Kemenkes RI) p 90-3

[5]   Thygesen K, *et al.* 2012 Third universal definition of myocardial infarction *Eur Heart J* **33** 2551-67

[6]   Montalescot G, *et al*. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the european society of cardiology *Eur Heart J* **34**(38) 2949-3003

[7]   Libby P 2002 Inflammation in atherosclerosis *Nature* **420**(6917) 868-74

[8]   Schoenhagen P, Ziada K M, Kapadia S R, Crowe T D, Nissen S E and Tuzcu E M 2000 Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study *Circulation* **101** 598–603

[9]   Hansson G K 2005 Mechanisms of disease: inflammation, atherosclerosis and coronary artery disease *N Engl J Med* **352** 1685-95

[10] Crea F and Liuzzo G 2013 Pathogenesis of acute coronary syndrome *J Am Coll Cardiol* **61** 1-11

[11] Libby P and Shi G P 2007 Mast cells as mediators and modulators of atherogenesis *Circulation* **115** 2471-3

[12] Clejan S, Japa S, Clemetson C, Hasabnis S S, David O and Talano JV 2002 Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis *J Cell Mol Med* **6**(4) 583-92

[13] Huang M, Pang X, Letourneau R, Boucher W and Theoharides T C 2002 Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in apolipoprotein-e knockout mice. *Cardiovasc Research* **55** 150-60

[14] Bot I, van Berkel T J C and Biessen E A L 2008 Mast cells: pivotal players in cardiovascular diseases *Current Cardiology Reviews* **4** 170-8

[15] Fahmida U, Wibowo Y and Ariawan I 2008 *Handbook Biostatistik 2: Intermediate Biostatistics for Nutrition and Health Researchers* (Jakarta: Seameo Tropmed Rccn) p 1-29;85-113

[16] O'Donnell C J and Elosua R 2008 Cardiovascular risk factors: insights from framingham heart study *Rev Esp Cardiol* **61**(3):299-310

[17]　Fox K A, *et al.* 2007 Decline in rates of death and heart failure in acute coronary syndrome 1999-2006 *JAMA* **297** 1892–900

[18]　Mandelzweig L, *et al*. 2006 The second euro heart survey on acute coronary syndrome: characteristics, treatment, and outcome of patients with acs in europe and the mediterranean basin in 2004 *Eur Heart J* **27** 2285–93

[19]　Zdravkovic V, Pantovic S, Rosic G, Tomic-Lucic A, Zdravkovic N, Colic M, Obradovic Z, Rosic M 2011 Histamine blood concentration in ischemic heart disease patients *J Biomed Biotechnol* **2011** 315709

[20]　Lucien C 1976 Grading of angina pectoris *Circulation* **54** 522-3

[21]　Wang K Y, *et al.* 2011 Histamine deficiency decrease atherosclerosis and inflammatory response in apolipoprotein e knockout mice independently of serum cholesterol level *Arterioscler Thromb Vasc Biol* **31** 800-7

[22]　Manduteanu I and Simionescu M 2012 Inflammation in atherosclerosis: a cause or a result of vascular disorders *J Cell Mol Med* **16**(9) 1978-90